New Russian pharma company created

28 December 2018

Russian financial conglomerate Sistema PJSFC today announced it has acquired an equity interest in JSC Pharmaceutical Enterprise Obolenskoe (OBL Pharm), a leading Russian pharmaceutical company.

The stake was acquired jointly with VTB Bank and management of OBL Pharm from Alvansa Ltd, which is majority-owned by Gazprombank and UFG Private Equity.

Sistema invested a total of 1.83 billion roubles ($2.66 million) in the acquisition of OBL Pharm, giving Sistema an effective stake of 11.7%.The investment consortium – consisting of Sistema, VTB and members of the OBL Pharm management team – collectively acquired 95.14% of OBL Pharm for a total investment of 15.5 billion roubles ($226 million).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK